Cognition Therapeutics Inc
CGTX- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001455365
No open-market purchases or sales by Cognition Therapeutics Inc insiders were filed in the last 90 days; 66 institutions reported holding it in 13F filings for Q2 2026, worth $26.0M in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Cognition Therapeutics Inc changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 28 | 31 | +3 |
| Shares | 5.19M | 5.09M | −95.5K (−1.8%) |
| Value | $11.4M | $9.67M | −$1.72M (−15.1%) |
New holders (7)
Institutions that held Cognition Therapeutics Inc at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Carlson Capital L P | 100,000 | $190.0K | 0.01% |
| Captrust Financial Advisors | 50,000 | $95.0K | 0.00% |
| Two Sigma Investments, LP | 24,407 | $46.0K | 0.00% |
| Wealth Alliance Advisory Group, LLC | 18,500 | $35.0K | 0.02% |
| State Street Corp | 14,650 | $28.0K | 0.00% |
| Northern Trust Corp | 14,116 | $27.0K | 0.00% |
| Royal Bank of Canada | 112 | $0 | 0.00% |
Sold out (4)
Institutions that held Cognition Therapeutics Inc at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Nantahala Capital Management, LLC | 192,752 | $407.0K |
| Prosight Management, LP | 120,198 | $254.0K |
| B. Riley Financial, Inc. | 30,904 | $65.0K |
| Two Sigma Advisers, LP | 15,600 | $33.0K |